Table 1. Baseline Characteristics of Patients.
| Crohn’s patients with SGI at baseline | |
|---|---|
| Age, mean (SD) | 43.9 (15.7) |
| Sex, N (%) | |
| Females | 85 (63%) |
| Males | 50 (37%) |
| Race, N (%) | |
| Caucasians | 82 (60.7%) |
| African Americans | 49 (36.3%) |
| Others | 4 (3.0%) |
| Duration of disease in years, mean (SD) | 9.6 (11.0) |
| Steroid use, N (%) | 57 (42.5%) |
| Tobacco use, N (%) | 30 (22.4%) |
| TNF blocker use, N (%) | 87 (64.9%) |
| VD use, N (%) | 20 (14.9%) |
| UST use, N (%) | 36 (26.9%) |
| Thiopurine, N (%) | 21 (15.7%) |
| MTX, N (%) | 16 (11.9%) |
| Crohn’s behavior, N (%) | |
| Penetrating | 52 (38.8%) |
| Stricturing | 35 (26.1%) |
| None | 47 (35.1%) |
| Perianal, N (%) | 40 (29.9%) |
| UGI, N (%) | 30 (22.4%) |
| Crohn’s location, N (%) | |
| Ileal | 23 (17%) |
| Colonic | 39 (28.9%) |
| Ileocolonic | 72 (53.3%) |
| BMI, mean (SD) | 26.8 (7.2) |
| Obesity, N (%) | 48 (35.8%) |
| PPI use, N (%) | 42 (31.3%) |
SD: standard deviation; SGI: serum genetic inflammatory; TNF: tumor necrosis factor; VD: vedolizumab; UST: ustekinumab; MTX: methotrexate; UGI: upper gastrointestinal; BMI: body mass index; PPI: proton pump inhibitor.